- Home
- ROIV vs OLED Comparison
ROIV vs OLED Comparison
Compare ROIV & OLED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | OLED |
|---|---|---|
| Founded | 2014 | 1985 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 7.1B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | ROIV | OLED |
|---|---|---|
| Price | $21.94 | $118.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $21.94 | ★ $181.33 |
| AVG Volume (30 Days) | ★ 6.5M | 516.5K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 1.52% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.64 |
| Revenue | $20,329,000.00 | ★ $639,977,000.00 |
| Revenue This Year | N/A | $2.50 |
| Revenue Next Year | $376.94 | $10.90 |
| P/E Ratio | ★ N/A | $25.47 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $103.70 |
| 52 Week High | $22.45 | $165.00 |
Technical Indicators
Market Signals| Indicator | ROIV | OLED |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 39.76 |
| Support Level | $20.14 | $120.16 |
| Resistance Level | $21.48 | $124.00 |
| Average True Range (ATR) | 0.66 | 2.80 |
| MACD | -0.02 | 1.20 |
| Stochastic Oscillator | 87.12 | 45.59 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About OLED Universal Display Corporation
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. The Company has one reportable business segment being OLED technologies and materials. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.